| Nov 17, 2009 | 08:00 | Infinity's IPI-504 Named One of Windhover and Campbell Alliance's "Top 10 Projects to Watch" in Oncology |
| Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Jeffrey Tong, Ph.D., vice president, corporate and product development, will present an overview of IPI-504 (retaspimycin hydrochloride), the company's intravenous heat shock protein 90 (Hsp90) chaperone inhibitor, at the Therapeutic Area Partnerships event tomorrow, November 18, 2009 at 3:30 p.m. EST. The conference, being held November 17-19, in Boston, showcases Windhover and Campbell Alliance's 2009 "Top 10 Projects to Watch" and partnership opportunities in oncology.
continued... |
|
| Nov 16, 2009 | 09:30 | Adelene Q. Perkins Named "Best Executive" at Annual Stevie(R) Awards Ceremony |
| Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Adelene Q. Perkins, president and chief business officer, was named the 2009 "Best Executive: Non-Services Business" in the 6th Annual Stevie Awards for Women in Business, presented at the Annual Award Dinner and Ceremony held on November 13, 2009 in New York City.
continued... |
|
| Nov 10, 2009 | 07:30 | Infinity to Present at Upcoming Conferences |
| Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that management will present a company overview at two upcoming conferences.
continued... |
|
| Nov 9, 2009 | 16:00 | Infinity Reports Recent R&D Highlights and Third Quarter 2009 Results |
| Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today reviewed recent R&D highlights and announced third quarter 2009 financial results.
continued... |
|
| Nov 2, 2009 | 06:30 | Infinity Announces Third Quarter 2009 Results Conference Call |
| Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, announced today that management will host a conference call on Monday, November 9, 2009 at 4:30 p.m. EST. In the conference call, management will review recent research and development and business highlights and Infinity's third quarter 2009 financial results.
continued... |
|
| Oct 7, 2009 | 07:00 | Infinity Announces Appointment of Dr. Thomas J. Lynch to Its Board of Directors |
| Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, announced today that Thomas J. Lynch, Jr., M.D., has been appointed to its Board of Directors.
continued... |
|
| Sep 2, 2009 | 07:00 | Infinity to Present At Upcoming Conferences |
| Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that management will present a company overview at several upcoming conferences.
continued... |
|
| Aug 5, 2009 | 16:15 | Infinity Reports Recent R&D Highlights and Second Quarter 2009 Results |
| Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today reviewed recent R&D highlights, provided updated 2009 guidance, and announced second quarter 2009 financial results.
continued... |
|
| Jul 30, 2009 | 06:30 | Infinity Announces Second Quarter 2009 Results Conference Call |
| Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, announced today that Infinity management will host a conference call on Thursday, August 6, 2009 at 8:30 a.m. EDT. In the conference call, management will review recent research and development and business highlights including Infinity's second quarter 2009 financial results.
continued... |
|
| Jul 23, 2009 | 16:40 | Infinity Paper On Discovery of Its Novel Hedgehog Inhibitor, IPI-926, Published in Journal of Medicinal Chemistry |
| Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that the chemistry and data leading to the discovery of its novel Hedgehog signaling pathway inhibitor, IPI-926, have been published in the Journal of Medicinal Chemistry. The paper, titled "Discovery of a Potent and Orally Active Hedgehog Pathway Antagonist (IPI-926)" and authored by Infinity's Martin R. Tremblay, Ph.D., Alfredo C. Castro, Ph.D., et al., is featured in today's issue of the journal (Volume 52, Issue 14, pages 4400-4418).
continued... |
|
| Jun 29, 2009 | 06:30 | Infinity Pharmaceuticals Added to Russell 2000(r) Index |
| Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that it was added to the Russell 2000(r) Index when Russell Investments reconstituted its comprehensive set of U.S. and global equity indexes on June 26, 2009. The Russell 2000, which is a subset of the Russell 3000(r) Index, measures the performance of the small-cap segment of U.S. equities. Membership in the Russell 2000 is reevaluated annually.
continued... |
|
| May 30, 2009 | 14:00 | Infinity Reports Encouraging Clinical Data for IPI-504 at ASCO 2009 |
| Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today presented promising data from two clinical trials of IPI-504, the company's heat shock protein 90 (Hsp90) chaperone inhibitor. Preliminary data from the Phase 2 portion of a study in patients with advanced non-small cell lung cancer (NSCLC) and a Phase 1 study of IPI-504 in combination with Taxotere(r) (docetaxel) demonstrate anti-tumor activity, including four partial responses in the Phase 2, and a generally well-tolerated safety profile in both studies. The data were presented during the 2009 American Society for Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida.
continued... |
|
| May 29, 2009 | 06:30 | New Paper in Science Features Infinity's IPI-926 Hedgehog Pathway Inhibitor as a Promising New Approach in Chemo-Resistant Pancreatic Cancer |
| Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, announced the recent publication of a new scientific paper further supporting Hedgehog signaling pathway inhibition as a promising new approach to treat cancer. The data featured in the paper show that IPI-926, when administered in combination with gemcitabine in a preclinical mouse model of treatment-resistant pancreatic cancer, increased tumor cell death, resulting in a reduction of tumor size and increased survival. These data suggest that IPI-926 may enable chemotherapeutic agents to successfully access and kill tumor cells. Infinity is currently evaluating IPI-926 in a Phase 1 clinical trial in patients with advanced solid tumors.
continued... |
|
| May 27, 2009 | 13:00 | Infinity Pharmaceuticals Named Winner of The Scientist's 'Best Places to Work in Industry' and Featured in Boston Business Journal's Best Places to Work 2009 Survey |
| Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that it has been named one of the "Best Places to Work" by both The Scientist and the Boston Business Journal.
continued... |
|
| May 13, 2009 | 07:30 | Clinical Data From Infinity's Hsp90 Chaperone Inhibitor Program to be Presented During ASCO Meeting |
| Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that it will be reporting clinical data on its novel Hsp90 chaperone inhibitor, IPI-504, during the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Orlando, Fla. from May 29 through June 2, 2009.
continued... |
|
| More >>
Total: 15 * all times are in the U.S. Eastern Time Zone
|
